Trial
NCT00787787
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
Adult Primary Hepatocellular Carcinoma
Intervention
sunitinib malate
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-01